Else Nutrition Holdings Inc (OTCQX:BABYF, TSX-V:BABY) said it has concluded a successful preclinical study on its plant-based infant formula on the pathway to bring its formulation to market.
The study results demonstrated proper growth similar to dairy-based infant formula, in a neonatal preclinical model, the company said.
Else noted that the results are a key first step on the path with the US Food and Drug Administration (FDA), as well as with other regulatory authorities, to demonstrate safety and nutrient bioavailability of the Else infant formula.
“This is a massive step forward for the company,” said Hamutal Yitzhak, CEO & co-founder of Else Nutrition in a statement. “Since inception, our vision has been to fill this major gap in the market, and to bring a clean label whole-food, plant-based, soy-free infant formula to millions of families worldwide."
READ: Else Nutrition says former American Academy of Pediatrics chair Dr Susan Baker to join its scientific advisory board
“These results mark further validation of our formulation, as we continue to push ahead in seeking FDA approval," she added.
The full study results will be presented at an international scientific conference on pediatric nutrition and growth in March 2022, the company said.
Else Nutrition is an Israel-based food and nutrition company focused on developing innovative, plant-based food and nutrition products for infants, toddlers, children, and adults.
Contact the author at jon.hopkins@proactiveinvestors.com